Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
OwnerGrant E. BLOUSE, Tom KNUDSEN +1inventors
InventorsGrant E. BLOUSE, Tom KNUDSEN, Howard LEVY
Life of this patent
Estimating the term…
Loading patent…
OwnerGrant E. BLOUSE, Tom KNUDSEN +1inventors
InventorsGrant E. BLOUSE, Tom KNUDSEN, Howard LEVY
Estimating the term…
Provided herein are modified FVII polypeptides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
A method of treating a bleeding event in a subject, comprising subcutaneously administering to the subject a dose of a modified Factor VIIa comprising modifications at least at a position corresponding to position 286 and at a position corresponding to position 298 in a FVII polypeptide comprising the sequence of amino acids set forth in SEQ ID NO:
5-27. (canceled)
31-41. (canceled)
43-45. (canceled)
47-50. (canceled)
52-53. (canceled)
56-60. (canceled)
63-68. (canceled)
70-71. (canceled)
73-74. (canceled)
76-83. (canceled)
(canceled)
The method of claim 186, wherein the modified FVIIa has kcat/km in a tissue-factor dependent assay that is greater than 100%, 150%, 200%, or 250% or more than unmodified FVIIa (SEQ ID NO:
88-90. (canceled)
(canceled)
(canceled)
(canceled)
103-108. (canceled)
111-127. (canceled)
129-131. (canceled)
A method of providing an on-demand treatment to a subject experiencing a bleed or to a subject likely to experience a bleed, comprising administering to the subject a subcutaneous dose of a modified FVIIa comprising modifications at least at a position corresponding to position 286 and at a position corresponding to position 298 in a FVII polypeptide comprising the sequence of amino acids set forth in SEQ ID NO:
137-143. (canceled)
(canceled)
147-151. (canceled)
154-162. (canceled)
164-166. (canceled)
A pharmaceutical composition for a single dosage subcutaneous administration, comprising a single therapeutically effective dose of a modified FVIIa in a pharmaceutically acceptable carrier for subcutaneous administration for an on-demand treatment of a bleed;
170-171. (canceled)
175-178. (canceled)
180-182. (canceled)
(canceled)
Dependencies are inferred from the claim text.